Insmed Incorporated is recruiting patients diagnosed with Nontuberculous Mycobacterial (NTM) lung infection that is caused by Mycobacterium avium complex (MAC) to enroll in a Phase 3 study. The purpose of the study is to test the efficacy and safety of a medication that has not been approved for use in the treatment of NTM called Liposomal Amikacin for Inhalation (LAI), given once a day using a nebulizer in patients with lung infection due to MAC that has not previously been successfully treated.
LAI will be administered in addition to standard therapy with other medications against lung infection called multi-drug therapy. The study is being conducted to learn the effects (good and bad) of the study drug LAI on you and your lung infection, test what the body does to the study drug, LAI and see if LAI improves your quality of life.
Patients must be 18 years of age or older at screening, and fulfill other eligibility criteria, including the willingness to stay on all of the prescribed medications for the duration of the study. For more information, please go to https://clinicaltrials.gov/ct2/show/NCT02344004.